Could Benefit of Plaque Removal Grow in Time?
A mathematical model predicts that a tiny difference in CDR-SB after two years of treatment would grow fivefold over the next three years as progression curves separate.
ALL NEWS
6654 RESULTS
Sort By:
- Most Recent
- Most Commented
Can ‘Cryptic Peptides’ Peg People with TDP-43 Pathology?
Mis-splicing events produce novel proteins that can be detected in the cerebrospinal fluid of ALS/FTD patients before their symptoms start.
In Amyloid Cascade, Do Reactive Astrocytes Bridge Plaques and Tangles?
Among cognitively healthy people, amyloid load tracked with blood p-tau181 and tangles only in those with high blood GFAP.
Field Loses Another Prominent Neuropathologist, Donald Price, 87
Known for his work on animal models, APP processing, and the cholinergic system, Price founded one of the first Alzheimer’s Disease Research Centers.
Not So Fast—The Brain Has Three Meningeal Membranes After All
Using live imaging, electron microscopy, and gene expression studies, two groups show that a purported fourth membrane is instead the inner layer of the arachnoid mater.
Meningeal Cuffs Around Veins Form Exit and Entry Ramps to the Brain
Using live imaging in mice, scientists found that tracers and immune cells move between brain and dura through gaps in the arachnoid mater around veins.
Gaining a Foothold: Amyloid Immunotherapy in Clinical Practice
Lecanemab will soon have maintenance dosing and subcutaneous formulations available; FDA advisory committee will consider donanemab June 10.
AI to Spot ARIA? FDA Says Yes
The commercial software icobrain aria sharpened radiologists’ detection of ARIA-E and ARIA-H. The FDA approved the technology for clinical use November 7.
Receptors and Broken Lysosomes Explain Risk from APOE Variants
ApoE4 transports toxic lipids into lysosomes. ApoE2 and Christchurch variants do not.
European Commission Greenlights Leqembi, at Last
The marketing authorization comes after delays and reversals. It excludes APOE4 homozygotes and people taking anticoagulants, and requires a post-market study.
Lithium Hinders Aβ Generation, Buffing Up GSK as Drug Target
The widely used psychiatric drug lithium, and other agents that inhibit glycogen synthase kinase-3 (GSK3), have been mentioned as possible Alzheimer's disease therapies for some time, primarily because GSK3 is one of several kinases known to phosphorylate tau...
Atorvastatin, Vaccine Trial Data Published
A mixed bag of epidemiologic studies alternatively hold up and knock down the promise that...
Love a Good Fight? Check Out Brouhaha Over Amyloid Imaging
As the first of a suite of PET β amyloid imaging agents stands poised to receive a ruling from the FDA, seven scientists are questioning the validity of this technology...
Presenilins Open Escape Hatch for ER Calcium
A paper out today in Cell proposes a novel role for presenilins in calcium signaling...
Chicago: Out of the Blue—A Tau-based Treatment for AD?
Of all clinical trials reported at the ICAD, one targeting the protein tau was the <em>therapy du jour</em>...
Current Filters
No filters selected